<DOC>
	<DOCNO>NCT02007174</DOCNO>
	<brief_summary>Blockade vascular endothelial growth factor ( VEGF ) bevacizumab use treat abnormal vascular condition anterior segment eye . In pterygium , anti-VEGF agent recently propose primary treatment , perioperative adjuvant , well treatment pterygia recurrence surgery . The aim present study prospectively evaluate effect three subconjunctival bevacizumab injection patient early pterygium recurrence . Materials Methods : The current study non-randomized single central trial . The method ensure allocation concealment sequentially number . Patients early pterygium recurrence select invited participate study . Recurrence define presence corneal vessel concomitant conjunctival hyperemia within first trimester primary pterygium removal , patient primary pterygium recurrence include . Patient related factor pregnancy , woman seek become pregnant , lactate woman exclude study . All patient receive three subconjunctival bevacizumab ( 2.5 mg/0.05 ml ) injection ( basal , 2 4 week ) recurrence area pterygium , photographed third , sixth twelfth month last bevacizumab injection . Photographic analysis perform take account two pterygium area : first measure include vessel area corneal surface , second measure include , , conjunctival corneal vessel area ( corneal-conjunctival area hyperemia ) . Neovascularization area pterygium determine use digital slit lam picture , analyze use Photoshop CS4 , order get pixel measurement lesion .</brief_summary>
	<brief_title>Bevacizumab Injection Recurrent Pterygium</brief_title>
	<detailed_description />
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients early pterygium recurrence select invited participate study . Recurrence define presence corneal vessel concomitant conjunctival hyperemia within first trimester primary pterygium removal , patient primary pterygium recurrence include Patient related factor pregnancy , woman seek become pregnant , lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>recurrent pterygium</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>triple dose</keyword>
</DOC>